TRUE DOSE TECHNOLOGY

Revolutionizing Therapeutic Drug Monitoring with Capillary Blood Sampling at Home

  • TrueDose introduces a groundbreaking approach to therapeutic drug monitoring (TDM), enabling precise and personalized chemotherapy dosing through home-based capillary blood sampling. Our innovative technology addresses the need for tailored treatment regimens by allowing patients to easily collect, preserve, and transport blood samples without leaving their homes.

What our kit does?

Empowering Home-Based Blood Sampling for Precision Medicine Across Therapeutic Areas

  • Our self-sampling kit is designed to be versatile, providing personalized therapeutic drug monitoring (TDM) for any medication with a narrow therapeutic dose window. This includes critical areas of medicine such as oncology, immune-medicine and psychiatry. By enabling patients to collect capillary blood samples from home, the kit reduces the need for frequent hospital visits, ensuring accurate and timely dose adjustments for improved treatment outcomes.   

                                                  

    We have already begun developing specialized products aimed at enhancing chemotherapy treatments, with a particular focus on female breast cancer patients. These innovations aim to improve dosing precision and patient care by integrating advanced TDM solutions into oncology.       

    Designed for convenience and accessibility, our self-sampling kit empowers breast cancer patients undergoing chemotherapy to collect capillary blood samples at home. This solution eliminates the need for frequent hospital visits, reducing both costs and intra-laboratory variability. The result is a more comfortable experience for patients, alongside optimized resource allocation for healthcare providers, ultimately enhancing patient care and societal benefits.

How it works?

Innovative Technology for Accurate Monitoring

  • The True Dose kit is designed for easy patient use and incorporates a unique technology with internal standards for accurate quantification. The internal standard is released during protein precipitation and mixes with the drug, ensuring that both the drug and the standard degrade at the same rate. This compensates for potential losses and eliminates the need for additional analytical preparation, which often introduces errors in other methods. Our method minimizes sample losses that vary between individuals and improves analysis by using stainless steel beads and extended storage time. Studies show that samples stored for 3–14 days result in better extraction, as both the drug and the internal standard require time to reach equilibrium in the blood, something not achievable with immediate analysis of whole blood samples.

Easy Collection

Patients can safely collect capillary blood via a simple finger prick. This process is non-invasive and designed for ease-of-use, providing patients with the convenience of performing it at home.

Once collected, the blood sample is stabilized within the kit to preserve its integrity throughout transport. Our device eliminates the need for cooling during shipment, ensuring that samples arrive in optimal condition for analysis.

Sample Preservation

After collection, samples are securely packaged and sent to our partner laboratories. The integrity of the sample is maintained, providing healthcare professionals with the accurate data necessary for making informed decisions regarding chemotherapy dosing.

Secure Transport

UPCOMING PRODUCTS IN DEVELOPMENT

Currently, our self-sampling kit is tailored specifically for breast cancer patients undergoing chemotherapy. Starting with breast cancer, we will expand our portfolio to include kits for a broader range of drugs with a narrow therapeutic dose window. This includes critical areas of medicine such as oncology, immune-medicine and psychiatry. Our goal is to extend the benefits of our technology to more patients, further advancing the standard of care in chronic disease treatment.

TECHNICAL SPECIFICATIONS

Data for the initial products will be presented once CE marking has been completed (currently in progress).

REGULATORY AND COMPLIANCE

High requirements for precision and security for medical devices intended for use in clinical diagnostics

  • The manufacturer's affirmation that products meet all the requirements applicable in relevant EU directives/regulations

  • Free movement on markets within the EU and EEA

  • Registered at competent authority (Läkemedelsverket)

  • CE marking required for in vitro diagnostic (IVD) medical devices to be placed on the market

What will this mean for True Dose once we launch our first           CE marked product portfolio second half of 2025?

  • Documentation and quality assurance of the product life cycle

  • Rigorous and structured verification and validation

  • Surveillance of all systems during use

  • Documented work processes and education of personnel

  • Responsibility for provable marketing